bioRxivCancer Biology
Targeting the dependence on PIK3C3-mTORC1 signaling in dormancy-prone breast cancer cells blunts metastasis initiation
I. E. Elkholi, A. Robert, C. Malouf, H. Kuasne, S. Drapela, G. Macleod, S. Hebert, A. Pacis, V. Calderon, C. L. Kleinman, A. P. Gomes, J. A. Aguirre-Ghiso, M. Park, S. Angers, J.-F. Cote
Abstract
Halting breast cancer metastatic relapses following primary tumor removal and the clinical dormant phase, remains challenging, due to a lack of specific vulnerabilities to target during dormancy. To address this, we conducted genome-wide CRISPR screens on two breast cancer cell lines with distinct dormancy properties: 4T1 (short-term dormancy) and 4T07 (prolonged dormancy). We discovered that loss of class-III PI3K, Pik3c3, revealed a unique vulnerability in 4T07 cells. Surprisingly, dormancy-prone 4T07 cells exhibited higher mTORC1 activity than 4T1 cells, due to lysosome-dependent signaling occurring at the cell periphery. Pharmacological inhibition of Pik3c3 counteracted this phenotype in 4T07 cells, and selectively reduced metastasis burden only in the 4T07 dormancy-prone model. This mechanism was also detected in human breast cancer cell lines in addition to a breast cancer patient-derived xenograft supporting that it may be relevant in humans. Our findings suggest dormant cancer cell-initiated metastasis may be prevented in patients carrying tumor cells that display PIK3C3-peripheral lysosomal signaling to mTORC1. Statement of SignificanceWe reveal that dormancy-prone breast cancer cells depend on the class III PI3K to mediate a constant peripheral lysosomal positioning and mTORC1 hyperactivity. Targeting this pathway might blunt breast cancer metastasis.
- organism: mouse
- organism: human
- assay: CRISPR screen
- assay: proteomics
- research focus: cell type annotation
- research focus: drug response / drug discovery
- research focus: differential expression
- approach: genetic perturbation / CRISPR
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer
P. Tallon de Lara, H. Castanon, … M. van den Broek·bioRxiv·Jun 2, 2020
- Natural killer cell regulation of breast cancer stem cells mediates metastatic dormancy.
G. G. Bushnell, D. Sharma, … M. S. Wicha·bioRxiv·Oct 2, 2023
- Tumor removal limits prostate cancer cell dissemination in bone and osteoblasts induce cancer cell dormancy through focal adhesion kinase
- Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during periods of clinical latency
M. Werner-Klein, A. Grujovic, … C. A. Klein·bioRxiv·May 28, 2020
- PERK inhibition blocks metastasis initiation by limiting UPR-dependent survival of dormant disseminated cancer cells
V. Calvo, W. Zheng, … J. A. Aguirre-Ghiso·bioRxiv·Jul 30, 2021
- Pericyte-tumor crosstalk facilitates metastatic tumor cell latency through PIEZO1-activated lysophospholipid transfer.
Tamara McErlain, Morgan J. Glass, … Meera Murgai·bioRxiv·Feb 15, 2025